三連板溢多利(300381.SZ):公司產品包含呼吸和免疫系統用藥原料藥
格隆匯2月6日丨溢多利(300381.SZ)公佈,公司股票於2020年2月4日、2020年2月5日、2020年2月6日連續三個交易日收盤價格漲幅偏離值累計超過20%,根據深圳證券交易所的有關規定,屬於股票交易異常波動的情況。
根據國家衞生健康委員會與國家中醫藥管理局於2020年1月27日聯合發佈的《新型冠狀病毒感染的肺炎診療議案(試行第四版)》,糖皮質激素可作為應對重症的治療用藥。公司的產品中包含呼吸和免疫系統用藥原料藥,主要產品有醋酸潑尼鬆、潑尼鬆龍、氫化可的鬆、倍他米鬆等多個糖皮質激素原料藥。
在醫用防護領域,公司工業酶產品中的糖化酶、澱粉酶主要用於發酵生產酒精,也是生產酒精必要原材料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.